A randomized, open-label, comparative, multi-center trial to evaluate the effects on hemostasis, lipids, carbohydrate metabolism, and on adrenal and thyroid function of a monophasic COC[combined oral contraceptive] containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [estradiol] compared to a monophasic COC containing 150 microg LNG[levonorgestrel] and 30 microg EE [ethinyl estradiol].

Trial Profile

A randomized, open-label, comparative, multi-center trial to evaluate the effects on hemostasis, lipids, carbohydrate metabolism, and on adrenal and thyroid function of a monophasic COC[combined oral contraceptive] containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [estradiol] compared to a monophasic COC containing 150 microg LNG[levonorgestrel] and 30 microg EE [ethinyl estradiol].

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Estradiol/nomegestrol (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Sponsors Organon
  • Most Recent Events

    • 01 Dec 2011 Results published in the European Journal of Contraception and Reproductive Health Care.
    • 09 Oct 2009 Actual patient number (121) added as reported by ClinicalTrials.gov.
    • 30 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top